US FDA grants priority vouchers to Merck's cholesterol pill, cancer therapyDec 19 (Reuters) - The U.S. Food and Drug Administration said on Friday it has granted national priority vouchers to Merck's MRK.N cholesterol pill and its cancer therapy, making them the latest additions to the fast-track program.
(Reporting by Siddhi Mahatole and Mariam Sunny in Bengaluru; Editing by Leroy Leo and Shailesh Kuber)
((siddhi.mahatole@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments